Asset
Tagmokitug
Coherus Oncology Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06657144 | phase1 | recruiting | 2025-04-01 | 2028-01-01 | Coherus Oncology, Inc. | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors |
| NCT05635643 | phase1 | active_not_recruiting | 2022-12-15 | 2026-09-30 | Coherus Oncology, Inc. | Study of CHS-114 in Participants With Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.